Kura Oncology KURA
NASDAQ KURA
$10.81 +0.16 (+1.50%)
As of: Oct 2, 2026 · 11:57 AM EDT

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)

Updated

Kura Oncology (KURA) reported Current Deferred Revenue of $55.48 million for Q2 2026, up 12.2% from $49.44 million a year earlier and up 16.3% from the prior quarter.

Analysis

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026) Analysis & Trends

At the end of FY2025, Kura Oncology posted Current Deferred Revenue of $48.98 million, up 101.8% from FY2024.

  • By year, Current Deferred Revenue came in at $24.27 million in FY2024.
  • Year over year, Current Deferred Revenue has now increased in each of the last three quarters.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $47.7 million (Q1 2026), $48.98 million (Q4 2025) and $48.75 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Kura Oncology 952.70 Mn 952.70 Mn 20.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 55.48 Mn
Mar 31, 2026 47.70 Mn
Dec 31, 2025 48.98 Mn
Sep 30, 2025 48.75 Mn
Jun 30, 2025 49.44 Mn
Mar 31, 2025 40.85 Mn
Dec 31, 2024 24.27 Mn
API Access

Kura Oncology Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=KURA&period=max&api_key=YOUR_API_KEY